Rivaroxaban

In medicine, rivaroxaban is an anticoagulant that inhibits factor Xa. Like warfarin, rivaroxaban is given orgally, but unlike warfarin rivaroxaban is administered in fixed doses without the need for coagulation monitoring.

History
Rivaroxaban was approved for use by the European Medicines Agency in 2009 "to prevent venous thromboembolism (VTE, the formation of clots in the veins) in adults who are undergoing surgery to replace a hip or knee."

Rivaroxaban has not been approved by the Food and Drug Administration in the United States.

Administration
Rivaroxaban is given orally

Deep venous thrombosis
Rivaroxaban can prevent embolism and thrombosis during perioperative care according to randomized controlled trials with two weeks of therapy after knee arthoplasty or 5 weeks of therapy after hip arthroplasty.